Patients Paying More for Cancer Drugs: An "Unintended Effect" of 340B Participation
Hospitals’ participation in Medicare’s 340B Drug Pricing Program may increase costs for cancer patients with commercial insurance.
Stay updated with breaking news from Drug Pricing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hospitals’ participation in Medicare’s 340B Drug Pricing Program may increase costs for cancer patients with commercial insurance.
In a state like Alabama, with a near-total abortion ban, access to contraception is critical for young women.
Global Rare Disease Drug Market Opportunity More Than USD 350 Million With More Than 1100 Drugs in Clinical Trials Says Kuick Research ...
CMS released revised guidance on Friday, adding transparency to the Medicare negotiation process it is engaging in with drug makers as part of the Inflation Reduction Act.
The impact of pharmacist on reducing medication expenses cannot be overstated as they leverage their medication management expertise within hospital settings through collaboration with the 340B program.